TBARS Assay

The TBARS (Thiobarbituric Acid Reactive Substances) assay is well-established for screening and monitoring lipid peroxidation. MDA forms a 1:2 adduct with thiobarbituric acid; the MDA-TBA adduct can then be measured.

Our OxiSelect™ TBARS Assay Kit provides a much more user-friendly protocol to measure the MDA-TBA adduct. Reaction volumes are much smaller than the traditional assay, so much less sample is required. Also, reactions can be performed in standard polypropylene tubes - no glass tubes or glass marbles are required.

1. Brindeiro, C.M. et al.(2012).Tempol Prevents Altered K+ Channel Regulation of Afferent Arteriolar Tone in Diabetic Rat Kidney. Hypertension.59:657 - 664. 
2. Joshi, S. G. et al. (2011). Nonthermal Dielectric-Barrier Discharge Plasma-Induced Inactivation Involves Oxidative DNA Damage and Memebrane Lipid Peroxidation in Escherichia coli. Antimicrob. Agents Chemother. 55:1053-1062.
3. Kasaikina, M.V. et al. (2011). Roles of the 15-kDa Selenoprotein (Sep15) in Redox Homeostasis and Cataract Development Revealed by the Analysis of Sep 15 Knockout Mice. J. Biol. Chem. 286:33203-33212.
4. Fedeles, B. I. et al. (2011). Chemical Genetics Analysis of an Aniline Mustard Anticancer Agent Reveals Complex I of the Electron Transport Chain as a Target. J. Biol. Chem. 286:33910-33920.
5. Kwon, H. et al. (2010). Vitamin D3 Upregulated Protein 1 Suppresses TNF-α–Induced NF- κB Activation in Hepatocarcinogenesis. J. Immunol. 185:3980-3989.
6. Wojciechowski, P. et al. (2010). Resveratrol Arrests and Regresses the Development of Pressure Overload- but Not Volume Overload-Induced Cardiac Hypertrophy in Rats. J. Nutr. 140:962-968.
7. Song, Y.R. et al. (2010). Activation of Hypoxia-Inducible Factor Attenuates Renal Injury in Rat Remnant Kidney. Nephrol. Dial. Transplant. 25:77-85.
8. Fomenko, D.E. et al. (2008). Methionine-R-sulfoxide reductase 1 (MsrB1) Knockout Mice: Roles of MsrB1 in Redox Regulation and Identification of a Novel Selenoprotein Form. J. Biol. Chem. 284:5986-5993.
9. Fujita, K. et al. (2008). Effectiveness of Antiplatelet Drugs Against Experimental Non-Alcoholic Fatty Liver Disease. Gut 57:1583-1591.